Page 16 - கொன்சில்ிும் மூலோபாய தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article GAITHERSBURG, Md., July 12, 2021 /PRNewswire/  MaxCyte, Inc., (LSE: MXCT) (LSE: MXCN), a leading provider of platform technologies for cell engineering ( MaxCyte or the Company ), today announced the public filing of a registration statement on Form S-1 with the Securities and Exchange Commission (the SEC ) for a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market (the offering ). The registration statement included a proposed change to the board of directors as well as unaudited financial information which is detailed below. Financial information in the Form S-1 registration statement The Company s Form S-1 registration statement contains unaudited consolidated financial statements for the period from 1 January 2021 to 31 March 2021 prepared in accordance with generally accepted accounting principles in the United States ( U.S. GAAP ). Such consolidated financial statements, as extracted

United statesCity ofUnited kingdomNick adamsDuncan monteith matthew odowdDoug doerflerAmanda murphyChris welshMary jane elliottEmma earl freddy crossleyPanmure gordonRon holtzRupert deardenMaxcyte incLondon stock exchangeMyeloid therapeutics inc